These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 11249685)

  • 1. The next generation of vaccines for the treatment of cancer.
    Long L; Glover RT; Kaufman HL
    Curr Opin Mol Ther; 1999 Feb; 1(1):57-63. PubMed ID: 11249685
    [No Abstract]   [Full Text] [Related]  

  • 2. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical development of MVA-based therapeutic cancer vaccines.
    Acres B; Bonnefoy JY
    Expert Rev Vaccines; 2008 Sep; 7(7):889-93. PubMed ID: 18767940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B7-1 gene-modified tumor cell vaccines.
    Antonia SJ
    Curr Opin Mol Ther; 1999 Feb; 1(1):50-6. PubMed ID: 11249684
    [No Abstract]   [Full Text] [Related]  

  • 5. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
    Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J
    Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costimulatory molecules in vaccine design.
    Hodge JW; Schlom J
    Ernst Schering Res Found Workshop; 2000; (30):23-52. PubMed ID: 10943315
    [No Abstract]   [Full Text] [Related]  

  • 7. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
    Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
    Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
    Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
    J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
    Aarts WM; Schlom J; Hodge JW
    Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity.
    Greiner JW; Zeytin H; Anver MR; Schlom J
    Cancer Res; 2002 Dec; 62(23):6944-51. PubMed ID: 12460911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carcinoembryonic antigen as a target for cancer vaccines.
    Hodge JW
    Cancer Immunol Immunother; 1996 Nov; 43(3):127-34. PubMed ID: 9001565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines: an innovative approach to treating cancer.
    Pazdur MP; Jones JL
    J Infus Nurs; 2007; 30(3):173-8. PubMed ID: 17505219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
    Seremet T; Brasseur F; Coulie PG
    Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRICOM: enhanced vaccines as anticancer therapy.
    Levy B; Panicalli D; Marshall J
    Expert Rev Vaccines; 2004 Aug; 3(4):397-402. PubMed ID: 15270644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of B7 costimulatory molecules as adjuvants in a prime-boost vaccination against Visna/Maedi ovine lentivirus.
    de Andrés X; Reina R; Ciriza J; Crespo H; Glaria I; Ramírez H; Grilló MJ; Pérez MM; Andrésdóttir V; Rosati S; Suzan-Monti M; Luján L; Blacklaws BA; Harkiss GD; de Andrés D; Amorena B
    Vaccine; 2009 Jul; 27(34):4591-600. PubMed ID: 19538997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenovirus transduction and culture conditions affect the immunogenicity of murine dendritic cells.
    Salucci V; Lena AM; Ciliberto G; Scarselli E; La Monica N
    Scand J Immunol; 2005 Sep; 62(3):206-17. PubMed ID: 16179007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor immunity and prolonged survival following combined adenovirus-HSP72 and CEA-plasmid vaccination.
    Myers AL; Krewet JA; Shah MR
    Vaccine; 2005 May; 23(27):3565-71. PubMed ID: 15855015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
    Morse MA; Clay TM; Hobeika AC; Osada T; Khan S; Chui S; Niedzwiecki D; Panicali D; Schlom J; Lyerly HK
    Clin Cancer Res; 2005 Apr; 11(8):3017-24. PubMed ID: 15837756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant.
    Loukinov D; Ghochikyan A; Mkrtichyan M; Ichim TE; Lobanenkov VV; Cribbs DH; Agadjanyan MG
    J Cell Biochem; 2006 Aug; 98(5):1037-43. PubMed ID: 16741971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.